Drugs / SODELGLITAZAR
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00437164 | Sep → Nov 2006 | type 2 diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT00264667 | Dec 2005 → Jun 2007 | metabolic syndrome X | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00196989 | Sep 2005 → Apr 2007 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SODELGLITAZAR | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104984 ↗ |
| Known as | GW677954 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00196989 ↗ |
| Modality | Small molecule | — CHEMBL2104984 ↗ |
| Route | Oral | “Oral GW677954 Capsules (2.5, 5, 10, 15 And 20 Mg Once A Day)” NCT00196989 ↗ |